Predicting Incidence of Dose Limiting Toxicities in Lymphoma Trials (2011 ASH Conference)

VIDEO | 01:00

Historically, older adults are underrepresented in clinical trials despite bearing a disproportionate burden of cancer. Clinical Director of the Lymphoma Outpatient Unit Paul Hamlin discusses an analysis that evaluates the relationship between DLT and SAE with increasing age and comorbidities in phase I lymphoma trials at Memorial Sloan Kettering.

The inverse correlation between age and travel distance to MSKCC implies travel is a potential barrier to participation and suggests availability of trials at satellite centers, when appropriate, may improve older patient participation.

This analysis suggests age and comorbidity should not unduly preclude participation of older individuals otherwise deemed appropriate for phase I studies in hematologic malignancy.